The Procter Gamble Company

Tomohiro Hakozaki

Leo Timothy Laughlin, Ii

Wenzhu Zhao

Bin Fang Deyer

John Erich Oblong

Jun Xu

Robert Lloyd Binder

Cheri Lynn Swanson

Matthew Clair Ehrman

Michael Koganov

Larry Richard Robinson

Shikhar Gupta

Deborah Ruth Finlay

Michael Christopher Sabino

Ankur Purwar

Charles Carson Bascom

Kevin John Mills

Leo Timothy Laughlin

Shuhei Tanaka

Teresa DiColandrea

Jesus Velazquez

Wan Ting Chung

John Crist Bierman

Dissanayake Mudiyanselage Mahathma Bandara Dissanayake

Jiazhen Wang

Jason Martin Winget

XiPing Ng

Heather Eileen Matheny

Shane Whitaker

Kurt Glen Kronholm

Jason Michael Price

Leo Timothy Ii Laughlin

Wai Kin Adams Kong

Ii Leo Timothy Laughlin

Peicong Yu

Disclosed is a method of improving the appearance of skin with a low-pH skin care composition that contains hydroxycinnamic acid (HCA) and a vitamin B3 compound in a synergistic combination.

Method of improving the appearance of skin

Methods and compositions for improving the appearance of skin are provided. The methods and compositions are especially suited for inhibiting activation of PAR2 in skin by utilizing a synergistic combination of a water lily extract and vitamin Bcompound. The method involves treating hyperpigmented skin by applying a skin care composition containing an effective amount of a combination of water lily extract and vitamin Bcompound to a target portion of skin over the course of a treatment period.

Skin care composition

Cellular energy levels in skin cells affected by oxidative stress can be improved through the use of a skin care composition that includes a sucrose ester and a fatty alcohol present at a specific ratio. The fatty alcohol and sucrose ester, when incorporated into a skin care composition at a specific ratio, can provide a synergistic improvement in cellular ATP level for skin cells suffering from the effects of oxidative stress.

Method of treating oxidative stress in skin and compositions therefor

An improved method of treating a skin barrier condition is disclosed. The method involves identifying a target portion of skin on a person where treatment is desired and applying a low-pH composition to the target portion of skin. The low-pH composition contains an effective amount of a vitamin Bcompound and has a pH of less than 5.0.

Method of treating a skin condition

Methods and compositions for improving the appearance of skin are provided. The methods and compositions are especially suited for improving sallow-looking skin by enhancing bilirubin degradation in skin. The methods and compositions herein utilize one or more sucrose esters, which demonstrate a surprising ability to reduce bilirubin levels. The method involves applying a skin care composition containing an effective amount of a sucrose ester to a target portion of skin where a reduction in bilirubin level is desired.

Low pH cosmetic compositions and methods for improving the appearance of skin. The low pH cosmetic compositions herein include a saccharide and, optionally, one or more additional skin care actives to improve the appearance of skin. The lower pH reduces or even eliminates some of the skin health and appearance drawbacks associated with saccharide induced glycation.

Composition and method for improving the appearance of skin

A skin care product is provided. The skin care product includes a multi-component skin care composition disposed in a multi-chamber container. The multi-component skin care composition includes an aqueous carrier component and a nicotinamide riboside component disposed in separate chambers, which prevents these components from contacting one another prior to use. The aqueous carrier component and the nicotinamide riboside component can be separated from one another by one or more fluid impermeable dividing members and/or activatable elements, which upon activation enable contact between the aqueous carrier component and nicotinamide riboside component.

Multi-component skin care product

A method of degrading bilirubin in skin is provided. The method involves identifying a target portion of skin where a reduction in bilirubin level is desired, and applying a vitamin B-containing, low-pH composition to the target portion of skin during a treatment period. The composition contains an effective amount of a vitamin Bcompound, has a pH of less than 5.0, and reduces bilirubin level in the target portion of skin during the treatment period. The amount of vitamin Bcompound and the pH of the composition may be selected to provide a synergistic reduction in bilirubin level, as compared to the reduction in bilirubin level provided by the same composition at a neutral pH.

Method for degrading bilirubin in skin

Human skin tissue sample methods and models for identifying and screening test agents as effective for providing skin tone benefits, methods for validating hypotheses for mechanisms driving skin pigmentation as well as methods for driving skin pigment levels in ex-vivo skin tissue. The method includes contacting a cultured human skin tissue sample with a test agent, generating a transcriptional profile from the sample, and comparing the results to a control to determine if the test agent is effective for providing a skin tone benefit.

Human skin sample methods and models for validating hypotheses for mechanisms driving skin pigmentation

A method of generating a hyperpigmentation condition gene expression signature for use in identifying connections between perturbagens and genes associated with a skin pigmentation condition. The method includes providing a gene expression profile for a reference sample of human skin cells not affected with a pigmentation condition; generating a gene expression profile for a sample of human skin cells from a subject exhibiting the hyperpigmentation condition; comparing the expression profiles to determine a gene expression signature that includes a set of differentially expressed genes; assigning an identifier to each gene constituting the gene expression signature and ordering the identifiers according to the direction of differential expression to create one or more gene expression signature lists; and storing the one or more gene expression signature lists on at least one computer readable medium.

Method of generating a hyperpigmentation condition gene expression signature

A method of formulating a skin-lightening composition by identifying actives with a data architecture and incorporating the actives into a skin care composition. The data architecture can be used to identify connections between perturbagens and genes associated with skin tone. A gene expression profile for a control human cell is compared to the gene expression profile a cell exposed to perturbagen to identify the genes which are differentially expressed. The differentially expressed genes are analyzed and arranged into an ordered list of identifiers, which along with other instances create a data architecture.

Method of formulating a skin-lightening composition

A method of constructing a data architecture for use in identifying connections between perturbagens and genes associated with skin tone. The method includes providing a gene expression profile for a control cell, generating a gene expression profile for a cell exposed to a perturbagen, identifying genes differentially expressed in response to the perturbagen, creating an ordered list of identifiers, storing the ordered list as an instance on a computer readable medium, and constructing a data architecture of stored instances.

Method of constructing a data architecture

Embodiments of screening methods for determining test agents effective for modifying the appearance of pigmented skin are provided. The screening method may comprise the steps of contacting a cell, a cell culture, or bulk cells with the test agent, wherein the cell, the cell culture, or the bulk cells comprise ADR&#x3b2;1 receptors, and determining based on the binding interaction of the test agent with the ADR&#x3b2;1 receptors whether the test agent is an effective ADR&#x3b2;1 receptor antagonist suitable for modifying the appearance of pigmented skin, wherein a test agent is considered to be an effective ADR&#x3b2;1 receptor antagonist when it defines a half maximal inhibitory concentration of less than about 1000 ppm.

Growing community of inventors

Cincinnati, OH, United States of America

Tomohiro Hakozaki